Biomedcode is pleased to announce that, the T2EDK program -development of a bronchoscopic biopsies-on-chip (BioOnChip) platform for immunotherapy drug screening in non-small cell lung cancer- initiated in collaboration with the BSRC Al. Fleming researcher M. Tsoumakidou, the Department of Computer Science and Biomedical Informatics of the University of Thessaly and the Pulmonary Clinic of the University of Ioannina has been financed by the European Union – Next Generation EU and the National Recovery and Resilience Plan Greece 2.0 funds. BioOnChip aims to explore the applicability of an innovative 3D microfluidic microculture, i.e. tumor-on-chip, in predicting real-time responses to PD1-blockade in NSCLC patients, that, if efficient, might have important socioeconomic impact.

 

Biomedcode is pleased to announce that, the T2EDK program -Spondylitis Evaluation Platform via non invasive Imaging Application tools (SEPIA)- initiated in collaboration with the developer of novel breakthrough imaging systems company BIOEMTECH, has been financed by the European Union and Greek national funds through the operational program Competitiveness, Entrepreneurship and Innovation under the call RESEARCH-CREATE-INNOVATE. SEPIA will combine the efforts of two innovative companies  aiming to develop precision imaging tools for the evaluation of the severity of Spondyloarthritis pathology developed in the TgA86 established mouse model of the pathology. Integration of these imaging tools in the sprondyloarthritis drug efficacy evaluation  platform will support the  preclinical development of novel therapies for Spondyloarthritis.

Biomedcode is pleased to announce that it has received funding from the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE supporting the innovative research network HUPLA that combines the efforts of industrial and renowned academic partners to develop precision drug evaluation tools  for the preclinical development of novel therapies for Multiple Sclerosis and Psoriasis. Read More

Biomedcode is pleased to announce that it has received national funding from the General Secretary for Research and Technology supporting the innovative research network BreastCaRANKL that combines the efforts of industrial and renowned academic partners to develop precision drug evaluation tools  for the preclinical development of novel therapies for  Breast Cancer. Read More